Drs. Sarina Elmariah and Pedro Bastos led an engaging ADVENT Industry Hub at EADV 2026 in Vienna, Austria, exploring the full systemic burden of prurigo nodularis (PN) beyond its visible nodules. The session highlighted how real-world evidence for approved biologics can inform treatment decisions and support long-term disease management across diverse patient populations.
Dr. Sarina Elmariah explores the complex systemic burden of PN, from diverse clinical presentations and delayed diagnosis to the profound impact of itch, sleep disruption, comorbidities, and reduced quality of life.

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
Explore the clinical features, complex burden, and underlying mechanisms of PN.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.